Physician profile
Daniel B Naul
NPI 1003234915
$2,826.08
in general payments reported to CMS, 2019-2025
30 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $403 · 2021: $419 · 2022: $606 · 2023: $478 · 2024: $288 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $986.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $666.31 | 2019-2025 | |
| Pfizer INC. | $495.64 | 2019-2025 | |
| Glaxosmithkline, LLC. | $455.89 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $130.81 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $123.53 | 2019-2023 | Wegovy, Saxenda |
| Janssen Pharmaceuticals, INC | $119.26 | 2019-2022 | |
| Lilly USA, LLC | $84.93 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $84.14 | 2019-2021 | |
| Abbott Laboratories | $74.96 | 2021-2023 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $61.89 | 2019-2020 | |
| Esperion Therapeutics, INC. | $52.15 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $50.57 | 2023-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $39.34 | 2019-2021 | |
| Eisai INC. | $34.34 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $30.20 | 2019-2024 | Camzyos |
| Amarin Pharma, INC. | $26.10 | 2019-2020 | |
| Genentech USA, INC. | $25.96 | 2020 | |
| Merck Sharp & Dohme LLC | $24.70 | 2019 | |
| Biogen, INC. | $20.99 | 2022 | |
| Allergan, INC. | $19.73 | 2020 | |
| Nevro Corp. | $17.38 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.29 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.21 | 2019 | |
| Seqirus USA INC | $15.03 | 2019 | |
| Bioventus LLC | $14.81 | 2019 | |
| Qiagen, LLC | $13.57 | 2020 | |
| Avanir Pharmaceuticals, INC. | $12.49 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.62 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Naul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.